X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ixekizumab (176) 176
psoriasis (122) 122
secukinumab (94) 94
index medicus (91) 91
dermatology (86) 86
humans (68) 68
double-blind (66) 66
brodalumab (61) 61
efficacy (48) 48
psoriasis - drug therapy (48) 48
safety (44) 44
severe plaque psoriasis (42) 42
ustekinumab (37) 37
il-17 (36) 36
moderate (33) 33
interleukin-17 (31) 31
treatment outcome (30) 30
arthritis (29) 29
interleukin-17 - antagonists & inhibitors (29) 29
etanercept (27) 27
adalimumab (26) 26
antibodies, monoclonal - therapeutic use (25) 25
antibodies, monoclonal, humanized - therapeutic use (25) 25
interleukins (24) 24
clinical trials (23) 23
female (23) 23
monoclonal-antibody (23) 23
plaque psoriasis (23) 23
psoriatic arthritis (23) 23
care and treatment (21) 21
male (21) 21
to-severe psoriasis (21) 21
cytokines (20) 20
monoclonal antibodies (20) 20
patients (20) 20
phase-iii (20) 20
psoriasis - immunology (20) 20
biologics (19) 19
interleukin 17 (19) 19
middle aged (19) 19
open-label (19) 19
severity of illness index (19) 19
interleukin-17 - immunology (18) 18
adult (17) 17
animals (17) 17
apremilast (17) 17
dermatologic agents - therapeutic use (17) 17
pharmacology & pharmacy (17) 17
rheumatoid-arthritis (16) 16
skin (16) 16
analysis (15) 15
immunology (15) 15
infliximab (15) 15
rheumatology (15) 15
rheumatoid arthritis (14) 14
th17 cells (14) 14
antibodies, monoclonal, humanized - adverse effects (13) 13
quality-of-life (13) 13
anti-interleukin-17 monoclonal-antibody (12) 12
dermatologic agents - adverse effects (12) 12
inflammation (12) 12
medicine & public health (12) 12
review (12) 12
guselkumab (11) 11
interleukin-17a (11) 11
anti-interleukin-17a monoclonal-antibody (10) 10
antibodies, monoclonal - adverse effects (10) 10
biologic (10) 10
controlled-trial (10) 10
double-blind method (10) 10
interleukin-12/23 monoclonal-antibody (10) 10
medicine, research & experimental (10) 10
pathogenesis (10) 10
phase-ii (10) 10
psoriasis - diagnosis (10) 10
quality of life (10) 10
therapy (10) 10
tofacitinib (10) 10
antibodies, monoclonal, humanized - administration & dosage (9) 9
chronic plaque psoriasis (9) 9
dermatologic agents (9) 9
health aspects (9) 9
placebo-controlled trial (9) 9
studies (9) 9
tildrakizumab (9) 9
trials (9) 9
biological products - therapeutic use (8) 8
cells (8) 8
clinical trials as topic (8) 8
drug therapy (8) 8
internal medicine (8) 8
ixekizumab treatment (8) 8
methotrexate (8) 8
randomized controlled trials as topic (8) 8
t-cells (8) 8
tnf-alpha (8) 8
tnf-α (8) 8
tumor necrosis factor-tnf (8) 8
abridged index medicus (7) 7
acitretin (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Actas Dermo-Sifiliograficas, ISSN 0001-7310, 07/2017, Volume 108, Issue 6, pp. 550 - 563
Background and objectives Ixekizumab demonstrated greater efficacy than placebo and etanercept in UNCOVER-3. Subgroup analysis of Latin American patients was... 
Psoriasis | Ixekizumab | Latin America
Journal Article
Actas Dermo-Sifiliograficas, ISSN 0001-7310, 07/2017, Volume 108, Issue 6, pp. 550 - 563
Background and objectives: Ixekizumab demonstrated greater efficacy than placebo and etanercept in UNCOVER-3. Subgroup analysis of Latin American patients was... 
Psoriasis | Ixekizumab | Latin America
Journal Article
Dermatology Online Journal, ISSN 1087-2108, 09/2018, Volume 24, Issue 9
We report a patient with severe psoriasis who failed to respond to phototherapy, conventional systemic treatment and four biologic agents (etanercept,... 
Anti-il17A | Psoriasis | Biologics | Ixekizumab
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 02/2019, Volume 139, Issue 2, pp. 316 - 323
In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical... 
MODERATE | REGISTER | SAFETY | IXEKIZUMAB | BRODALUMAB | PHASE-3 | EPIDEMIOLOGY | DERMATOLOGY
Journal Article
ACTA DERMATO-VENEREOLOGICA, ISSN 0001-5555, 10/2019, Volume 99, Issue 11, pp. 1031 - 1032
Journal Article
JOURNAL OF INVESTIGATIVE DERMATOLOGY, ISSN 0022-202X, 12/2017, Volume 137, Issue 12, pp. 2642 - 2644
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 01/2019, Volume 19, Issue 1, pp. 45 - 54
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 11/2019
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 09/2019
Journal Article
Actas Dermo-Sifiliograficas, ISSN 0001-7310, 05/2017, Volume 108, Issue 4, pp. 305 - 314
Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in... 
Psoriasis | Anti-IL-17 agents | Interleukin-17 | Ixekizumab
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 04/2018, Volume 98, Issue 4, pp. 456 - 457
Journal Article
Journal of Dermatological Treatment, ISSN 0954-6634, 2019, pp. 1 - 6
Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, has shown superiority to ustekinumab (UST) and etanercept in... 
ixekizumab | interleukin-17A | ustekinumab | Cumulative clinical benefits | psoriasis
Journal Article
Expert Review of Clinical Immunology, ISSN 1744-666X, 11/2019, Volume 15, Issue 11, pp. 1185 - 1194
Introduction: Psoriasis is a chronic, immune-mediated disease with significant associated comorbidities. Its pathogenesis is likely multifactorial, however,... 
ixekizumab | interleukin-17 inhibitors | Biologics | psoriasis | IL-17 | secukinumab | brodalumab
Journal Article
Actas Dermo-Sifiliográficas (English Edition), ISSN 1578-2190, 07/2017, Volume 108, Issue 6, pp. 550 - 563
Ixekizumab demonstrated greater efficacy than placebo and etanercept in UNCOVER-3. Subgroup analysis of Latin American patients was performed. We report... 
Latinoamérica | Psoriasis | Soriasis | Ixekizumab | Latin America
Journal Article
Actas Dermo-Sifiliográficas (English Edition), ISSN 1578-2190, 09/2019, Volume 110, Issue 7, pp. 585 - 589
Ixekizumab has proven efficacy and safety for the treatment of psoriasis in clinical trials. The aim of this study was to evaluate its effectiveness and safety... 
Práctica clínica habitual | Routine clinical practice | Psoriasis | Ixekizumab
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 07/2019, Volume 81, Issue 1, pp. 173 - 178
Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies... 
ixekizumab | biologics | drug survival | psoriasis | IL-17 | secukinumab | MULTICENTER | EFFICACY | SAFETY | DERMATOLOGY | Psoriasis | Interleukins | Pharmaceutical industry | Analysis
Journal Article
JAAD Case Reports, ISSN 2352-5126, 01/2018, Volume 4, Issue 1, pp. 22 - 23
Journal Article
Nature Reviews Rheumatology, ISSN 1759-4790, 07/2015, Volume 11, Issue 7, pp. 415 - 429
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.